Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Changes in cytogenetics and molecular genetics in acute myeloid leukemia from childhood to adult age groups

U. Creutzig, M. Zimmermann, D. Reinhardt, M. Rasche, C. von Neuhoff, T. Alpermann, M. Dworzak, K. Perglerová, Z. Zemanova, J. Tchinda, J. Bradtke, C. Thiede, C. Haferlach,

. 2016 ; 122 (24) : 3821-3830. [pub] 20160816

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc17023772

BACKGROUND: To obtain better insight into the biology of acute myeloid leukemia (AML) in various age groups, this study focused on the genetic changes occurring during a lifetime. METHODS: This study analyzed the relation between age and genetics from birth to 100 years in 5564 patients with de novo AML diagnosed from 1998 to 2012 (1192 patients from nationwide pediatric studies [AML Berlin-Frankfurt-Münster studies 98 and 2004] and 4372 adults registered with the Munich Leukemia Laboratory). RESULTS: The frequencies of cytogenetic subgroups were age-dependent. Favorable subtypes (t(8;21), inv(16)/t(16;16), and t(15;17)) decreased in general from the pediatric age group (2 to < 18 years; 33%) to the oldest groups (<5% for > 70 years; P < .0001). Unfavorable cytogenetics (-7/del(7), -5/del(5q) or 5p, inv(3)/t(3;3), t(6;9), complex karyotype, 12p, 17p, and 11q23/mixed-lineage leukemia aberrations, excluding t(9;11)) were frequent (42%) in infants (<2 years), had a low frequency in children and young adults (<22%), and increased in frequency up to 36% in patients older than 85 years (P = .01). This was even more significant for complex karyotypes (P ≤ .0001), which also showed a strong increase in the absolute age-specific incidence with age. Interestingly, the frequency of 11q23 abnormalities decreased from infants to older patients. The proportion of clinically relevant molecular aberrations of CCAAT/enhancer binding protein α, nucleophosmin (NPM1), and NPM1/fms-related tyrosine kinase 3-internal tandem duplication increased with age. CONCLUSIONS: Altogether, with the exclusion of infants, a significant decrease in the proportion of favorable cytogenetic subtypes and an increase in unfavorable cytogenetics were observed with increasing age. These findings indicate different mechanisms for the pathogenesis of AML; these different mechanisms also suggest directions for etiological research and contribute to the more unfavorable prognosis with increasing age. Cancer 2016;122:3821-3830. © 2016 American Cancer Society.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17023772
003      
CZ-PrNML
005      
20170829113610.0
007      
ta
008      
170720s2016 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/cncr.30220 $2 doi
035    __
$a (PubMed)27529519
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Creutzig, Ursula $u Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany.
245    10
$a Changes in cytogenetics and molecular genetics in acute myeloid leukemia from childhood to adult age groups / $c U. Creutzig, M. Zimmermann, D. Reinhardt, M. Rasche, C. von Neuhoff, T. Alpermann, M. Dworzak, K. Perglerová, Z. Zemanova, J. Tchinda, J. Bradtke, C. Thiede, C. Haferlach,
520    9_
$a BACKGROUND: To obtain better insight into the biology of acute myeloid leukemia (AML) in various age groups, this study focused on the genetic changes occurring during a lifetime. METHODS: This study analyzed the relation between age and genetics from birth to 100 years in 5564 patients with de novo AML diagnosed from 1998 to 2012 (1192 patients from nationwide pediatric studies [AML Berlin-Frankfurt-Münster studies 98 and 2004] and 4372 adults registered with the Munich Leukemia Laboratory). RESULTS: The frequencies of cytogenetic subgroups were age-dependent. Favorable subtypes (t(8;21), inv(16)/t(16;16), and t(15;17)) decreased in general from the pediatric age group (2 to < 18 years; 33%) to the oldest groups (<5% for > 70 years; P < .0001). Unfavorable cytogenetics (-7/del(7), -5/del(5q) or 5p, inv(3)/t(3;3), t(6;9), complex karyotype, 12p, 17p, and 11q23/mixed-lineage leukemia aberrations, excluding t(9;11)) were frequent (42%) in infants (<2 years), had a low frequency in children and young adults (<22%), and increased in frequency up to 36% in patients older than 85 years (P = .01). This was even more significant for complex karyotypes (P ≤ .0001), which also showed a strong increase in the absolute age-specific incidence with age. Interestingly, the frequency of 11q23 abnormalities decreased from infants to older patients. The proportion of clinically relevant molecular aberrations of CCAAT/enhancer binding protein α, nucleophosmin (NPM1), and NPM1/fms-related tyrosine kinase 3-internal tandem duplication increased with age. CONCLUSIONS: Altogether, with the exclusion of infants, a significant decrease in the proportion of favorable cytogenetic subtypes and an increase in unfavorable cytogenetics were observed with increasing age. These findings indicate different mechanisms for the pathogenesis of AML; these different mechanisms also suggest directions for etiological research and contribute to the more unfavorable prognosis with increasing age. Cancer 2016;122:3821-3830. © 2016 American Cancer Society.
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a dítě $7 D002648
650    _2
$a předškolní dítě $7 D002675
650    _2
$a chromozomální aberace $7 D002869
650    _2
$a cytogenetické vyšetření $x metody $7 D020732
650    _2
$a cytogenetika $x metody $7 D003582
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a kojenec $7 D007223
650    _2
$a novorozenec $7 D007231
650    _2
$a karyotypizace $7 D007621
650    _2
$a akutní myeloidní leukemie $x genetika $x patologie $7 D015470
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a molekulární biologie $x metody $7 D008967
650    _2
$a prognóza $7 D011379
650    _2
$a mladý dospělý $7 D055815
655    _2
$a časopisecké články $7 D016428
700    1_
$a Zimmermann, Martin $u Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany.
700    1_
$a Reinhardt, Dirk $u Department of Pediatric Hematology-Oncology, University of Duisburg-Essen, Essen, Germany.
700    1_
$a Rasche, Mareike $u Department of Pediatric Hematology-Oncology, University of Duisburg-Essen, Essen, Germany.
700    1_
$a von Neuhoff, Christine $u Department of Pediatric Hematology-Oncology, University of Duisburg-Essen, Essen, Germany.
700    1_
$a Alpermann, Tamara $u Munich Leukemia Laboratory, Munich, Germany. $7 gn_A_00004764
700    1_
$a Dworzak, Michael $u Department of Pediatrics, St. Anna Children's Hospital and Children's Cancer Research Institute, Medical University of Vienna, Vienna, Austria.
700    1_
$a Perglerová, Karolína $u Munich Leukemia Laboratory 2 SRO, Prague, Czech Republic.
700    1_
$a Zemanova, Zuzana $u Center of Oncocytogenetics, Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital and First Faculty of Medicine, Charles University, Prague, Czech Republic.
700    1_
$a Tchinda, Joelle $u Pediatric Hematology/Oncology, University of Zurich, Zurich, Switzerland.
700    1_
$a Bradtke, Jutta $u Institute for Pathology, University Hospital of Giessen and Marburg, Giessen, Germany.
700    1_
$a Thiede, Christian $u Medical Clinic and Policlinic I, Carl Gustav Carus University Hospital, Technical University, Dresden, Germany.
700    1_
$a Haferlach, Claudia $u Munich Leukemia Laboratory, Munich, Germany.
773    0_
$w MED00001031 $t Cancer $x 1097-0142 $g Roč. 122, č. 24 (2016), s. 3821-3830
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27529519 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170720 $b ABA008
991    __
$a 20170829114157 $b ABA008
999    __
$a ok $b bmc $g 1239453 $s 984685
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 122 $c 24 $d 3821-3830 $e 20160816 $i 1097-0142 $m Cancer $n Cancer $x MED00001031
LZP    __
$a Pubmed-20170720

Najít záznam

Citační ukazatele

Možnosti archivace